BioSpace News Archive

Medicure Inc. (“Medicure”) (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, will release financial results for the first quarter ended March 31, 2018 on Wednesday, May 23, 2018.

Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today provided a corporate update and announced financial results for the first quarter ended March 31, 2018.

Australian immuno-oncology company Minomic International Ltd is pleased to announce the completion of its prospective clinical trial of the company’s novel prostate cancer diagnostic test, MiCheck®.

TRANSGENE (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies against cancers and infectious diseases, announces that new clinical data on the oncolytic virus Pexa-Vec will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place from 1 to 5 June in Chicago.

Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the European Commission (EC) has approved Cabometyx® (cabozantinib) 20, 40, 60 mg for the first-line treatment of adults with intermediate- or poor-risk advanced renal cell carcinoma (aRCC).

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of new cancer therapies, announced its financial results for the third quarter ended March 31, 2018. DelMar executive management will host a business update conference call for investors, analysts and other interested parties on May 30, 2018 at 4:30 p.m. Eastern Time.

Safety Review Committee (SRC) recommends proceeding to the second dosing cohort of PCM-075 in combination with low-dose cytarabine (LDAC) in dose-escalation phase of trial

Navitor Pharmaceuticals to Present at UBS Global Healthcare Conference

Amneal Pharmaceuticals, Inc. (NYSE: AMRX), today announced it has received final U.S. Food and Drug Administration (FDA) approval for a generic version of Welchol® (colesevelam HCI).

Innovative immuno-therapy company welcomes proven leaders in pharma and therapeutics